Clinical trial

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

NCT07368543

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Sacituzumab Govitecan Normalized identity: sacituzumab govitecanView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Trastuzumab Deruxtecan Normalized identity: trastuzumab deruxtecanView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-01-16

PhasePHASE2

Conditions

Metastatic Breast Cancerunresolved

Interventions

Sacituzumab GovitecanDRUG · verified · RxNorm: sacituzumab govitecan

Trastuzumab DeruxtecanDRUG · verified · RxNorm: trastuzumab deruxtecan

Sponsors & collaborators

Fudan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07368543 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.